CO5190700A1 - COMPUESTOS DE IMIDAZO[1,5-a]-PIRIDO[3,2-e]PIRAZONAS, PROCEDI MIENTO PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN . . . . . - Google Patents

COMPUESTOS DE IMIDAZO[1,5-a]-PIRIDO[3,2-e]PIRAZONAS, PROCEDI MIENTO PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN . . . . .

Info

Publication number
CO5190700A1
CO5190700A1 CO00002747A CO00002747A CO5190700A1 CO 5190700 A1 CO5190700 A1 CO 5190700A1 CO 00002747 A CO00002747 A CO 00002747A CO 00002747 A CO00002747 A CO 00002747A CO 5190700 A1 CO5190700 A1 CO 5190700A1
Authority
CO
Colombia
Prior art keywords
alkyl
aryl
several times
once
unsaturated
Prior art date
Application number
CO00002747A
Other languages
English (en)
Spanish (es)
Inventor
Norbert Hofgen
Stefan Szelenyi
Marx Degenhard
Egerland Ute
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Publication of CO5190700A1 publication Critical patent/CO5190700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO00002747A 1999-01-20 2000-01-19 COMPUESTOS DE IMIDAZO[1,5-a]-PIRIDO[3,2-e]PIRAZONAS, PROCEDI MIENTO PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN . . . . . CO5190700A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen

Publications (1)

Publication Number Publication Date
CO5190700A1 true CO5190700A1 (es) 2002-08-29

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00002747A CO5190700A1 (es) 1999-01-20 2000-01-19 COMPUESTOS DE IMIDAZO[1,5-a]-PIRIDO[3,2-e]PIRAZONAS, PROCEDI MIENTO PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN . . . . .

Country Status (23)

Country Link
EP (1) EP1144410A2 (id)
JP (1) JP2002535330A (id)
KR (1) KR20010101603A (id)
CN (1) CN1344268A (id)
AR (1) AR022318A1 (id)
AU (1) AU2291200A (id)
BG (1) BG105714A (id)
BR (1) BR0007613A (id)
CA (1) CA2296224A1 (id)
CO (1) CO5190700A1 (id)
CZ (1) CZ20012627A3 (id)
EA (1) EA200100792A1 (id)
EE (1) EE200100377A (id)
HU (1) HUP0105132A3 (id)
ID (1) ID29790A (id)
IL (1) IL144156A0 (id)
IS (1) IS5987A (id)
LT (1) LT2001078A (id)
LV (1) LV12793B (id)
NO (1) NO20013334L (id)
SK (1) SK10322001A3 (id)
TR (1) TR200102121T2 (id)
WO (1) WO2000043392A2 (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1461022A2 (en) * 2001-12-17 2004-09-29 ALTANA Pharma AG Use of selective pde5 inhibitors for treating partial and global respiratory failure
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
KR101555384B1 (ko) * 2006-12-13 2015-09-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
WO2009070584A1 (en) 2007-11-30 2009-06-04 Wyeth Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
CN106905324B (zh) 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
US9938284B2 (en) 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
ES2971969T3 (es) 2015-07-07 2024-06-10 H Lundbeck As Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas
CN117843645A (zh) 2018-05-25 2024-04-09 伊马拉公司 一种pde9抑制剂的一水合物和结晶形态

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
IL144156A0 (en) 2002-05-23
AR022318A1 (es) 2002-09-04
IS5987A (is) 2001-06-29
HUP0105132A3 (en) 2002-12-28
AU2291200A (en) 2000-08-07
WO2000043392A3 (de) 2000-09-28
CZ20012627A3 (cs) 2002-01-16
LT2001078A (en) 2002-08-26
JP2002535330A (ja) 2002-10-22
KR20010101603A (ko) 2001-11-14
BR0007613A (pt) 2001-10-30
CN1344268A (zh) 2002-04-10
TR200102121T2 (tr) 2002-01-21
CA2296224A1 (en) 2000-07-20
SK10322001A3 (sk) 2002-07-02
LV12793B (lv) 2002-05-20
NO20013334D0 (no) 2001-07-05
BG105714A (en) 2002-02-28
WO2000043392A2 (de) 2000-07-27
EE200100377A (et) 2002-10-15
EP1144410A2 (de) 2001-10-17
EA200100792A1 (ru) 2002-10-31
HUP0105132A2 (hu) 2002-05-29
NO20013334L (no) 2001-07-05
LV12793A (lv) 2002-02-20
ID29790A (id) 2001-10-11

Similar Documents

Publication Publication Date Title
CO5190700A1 (es) COMPUESTOS DE IMIDAZO[1,5-a]-PIRIDO[3,2-e]PIRAZONAS, PROCEDI MIENTO PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN . . . . .
CR20110380A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal (divisional exp. 8266)
HRP20050712A2 (en) SUBSTITUTED HEXAHYDROPYRAZINO[1,2-a]PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS
UY27779A1 (es) Compuestos químicos
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
Shurpik et al. Supramolecular neuromuscular blocker inhibition by a pillar [5] arene through aqueous inclusion of rocuronium bromide
ES2178268T3 (es) Formulaciones de liberacion controlada.
DE60239871D1 (de) Cucurbiturilderivate, die in wasser und organischen lösungsmitteln löslich sind, verfahren zu deren herstellung, verfahren zu deren trennung und deren anwendung
EA199900303A2 (ru) Замещенные трициклические соединения
UY28733A1 (es) Compuestos quimicos
PA8632601A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
FI103668B1 (fi) Menetelmä farmakologisesti aktiivisten pyrrolo[3,2-e]indol-4(5H)-onidimeerien valmistamiseksi
MX9400070A (es) Compuestos heterociclicos, un procedimiento para prepararlos, su uso y composiciones farmaceuticas que los contienen.
ES2059931T3 (es) Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular.
MX9400253A (es) Derivados de piperazina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
ECSP045372A (es) Inhibidores de la carboxipeptidasa b plasmática
PE86698A1 (es) Derivados de indolina
ES2132283T3 (es) Derivados n-heteroaril sustituidos de propanamida utiles en el tratamiento de enfermedades cardiovasculares.
AR029617A1 (es) Procedimiento para preparar secretagogos de hormonas del crecimiento y polimorfo de los compuestos obtenidos
BR0214173A (pt) Processo para reagir alcalóides, produto de reação, mistura de produtos de reação, e, uso de produtos de reação
ES2153789B1 (es) Procedimiento para la obtencion de 178-(n-terc-butlcarbamoil)-3-ona-4-aza-esteroides
Coantic-Castex et al. The remarkable UV light invulnerability of thymine GNA dinucleotides
DE60132339D1 (de) Verbindungen in form homodimerer oder heterodimerer prodrugs; verfahren zur herstellung dieser prodrugs und deren pharmakologisch verträglichen salzen und verwendung von verbindungen in der behandlung von phosphodiesterase vermittelten krankheiten und funktionsstörungen
ES2152571T3 (es) Procedimiento para la preparacion de dioxoazabiciclohexanos.
Palao et al. Exploring BODIPY meso-enamines as singlet-oxygen photosensitizers for PDT.

Legal Events

Date Code Title Description
FA Application withdrawn